Evaluation of multidrug efflux pump inhibitors by a new method using microfluidic channels

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Matsumoto, Yoshimi ^a   Hayama, Kohei ^a   Sakakihara, Shouichi ^a   Nishino, Kunihiko ^a,b   Noji, Hiroyuki ^a,b,c   Iino, Ryota ^a,b,c   Yamaguchi, Akihito ^a  

^a OSAKA UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZTREONAM; CIPROFLOXACIN; D 13 9001; ERYTHROMYCIN; FLUORESCEIN DERIVATIVE; FLUORESCEIN DI BETA DEXTRO GALACTOPYRANOSIDE; PHENYLARGININE BETA NAPHTHYLAMIDE; POLYMYXIN B; POLYMYXIN B NONAPEPTIDE; PYRIDOPYRIMIDINE; UNCLASSIFIED DRUG; CARRIER PROTEIN;

ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; CELL COUNT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DELETION MUTANT; DRUG POTENTIATION; DRUG STRUCTURE; ESCHERICHIA COLI; FLUORESCENCE; FLUORESCENCE MICROSCOPE; HYDROLYSIS; MEMBRANE PERMEABILITY; MEXAB OPRM GENE; MEXXY OPRM GENE; MICROFLUIDIC ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLASMID; PSEUDOMONAS AERUGINOSA; DRUG EFFECT; DRUG SCREENING; FLUORESCENCE MICROSCOPY; GENETICS; INSTRUMENTATION; MICROBIOLOGICAL EXAMINATION; MICROFLUIDICS;

ESCHERICHIA COLI; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; DRUG EVALUATION, PRECLINICAL; GENES, BACTERIAL; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MICROFLUIDICS; MICROSCOPY, FLUORESCENCE; PLASMIDS; PSEUDOMONAS AERUGINOSA;

EID: 79954553031     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018547     Document Type: Article

References (45)

1. Kirikae T, Mizuguchi Y, Arakawa Y, (2008) Investigation of isolation rates of Pseudomonas aeruginosa with and without multidrug resistance in medical facilities and clinical laboratories in Japan. J Antimicrob Chemother 61: 612-615.
2. Sekiguchi J, Teruya K, Horii K, Kuroda E, Konosaki H, et al. (2007) Molecular epidemiology of outbreaks and containment of drug-resistant Pseudomonas aeruginosa in a Tokyo hospital. J Infect Chemother 13: 418-422.
3. Sekiguchi J, Asagi T, Miyoshi-Akiyama T, Kasai A, Mizuguchi Y, et al. (2007) Outbreaks of multidrug-resistant Pseudomonas aeruginosa in community hospitals in Japan. J Clin Microbiol 45: 979-989.
4. Satoh R, Tsukada H, Tanabe Y, Tamura Y, Yamamoto T, et al. (2008) An outbreak and isolation of drug-resistant Pseudomonas aeruginosa at Niigata University Hospital, Japan. J Infect Chemother 14: 325-329.
5. Livermore DM, (2002) Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare? Clinical Infectious Diseases 34: 634-640.
6. Lister PD, Wolter DJ, Hanson ND, (2009) Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22: 582-610.
7. Ryan BM, Dougherty TJ, Beaulieu D, Chuang J, Dougherty BA, et al. (2001) Efflux in bacteria: what do we really know about it? Expert Opin Investig Drugs 10: 1409-1422.
8. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, et al. (2000) Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 44: 3322-3327.
9. Schweizer HP, (2003) Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions. Genet Mol Res 2: 48-62.
10. Llanes C, Hocquet D, Vogne C, Benali-Baitich D, Neuwirth C, et al. (2004) Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously. Antimicrob Agents Chemother 48: 1797-1802.
11. Morita Y, Kimura N, Mima T, Mizushima T, Tsuchiya T, (2001) Roles of MexXY- and MexAB-multidrug efflux pumps in intrinsic multidrug resistance of Pseudomonas aeruginosa PAO1. J Gen Appl Microbiol 47: 27-32.
12. Mesaros N, Glupczynski Y, Avrain L, Caceres NE, Tulkens PM, et al. (2007) A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa. J Antimicrob Chemother 59: 378-386.
13. Henrichfreise B, Wiegand I, Pfister W, Wiedemann B, (2007) Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob Agents Chemother 51: 4062-4070.
14. Giske CG, Buaro L, Sundsfjord A, Wretlind B, (2008) Alterations of porin, pumps, and penicillin-binding proteins in carbapenem resistant clinical isolates of Pseudomonas aeruginosa. Microb Drug Resist 14: 23-30.
15. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, et al. (2001) Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 45: 105-116.
16. Tohidpour A, Peerayeh SN, Mehrabadi JF, Yazdi HR, (2009) Determination of the Efflux Pump-Mediated Resistance Prevalence in Pseudomonas aeruginosa, Using an Efflux Pump Inhibitor. Current Microbiology 59: 352-355.
17. Sennhauser G, Bukowska MA, Briand C, Grutter MG, (2009) Crystal Structure of the Multidrug Exporter MexB from Pseudomonas aeruginosa. Journal of Molecular Biology 389: 134-145.
18. Murakami S, Nakashima R, Yamashita E, Matsumoto T, Yamaguchi A, (2006) Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature 443: 173-179.
19. Russo-Marie F, Roederer M, Sager B, Herzenberg LA, Kaiser D, (1993) Beta-galactosidase activity in single differentiating bacterial cells. Proc Natl Acad Sci U S A 90: 8194-8198.
20. Yang NC, Hu ML, (2004) A fluorimetric method using fluorescein di-beta-D-galactopyranoside for quantifying the senescence-associated beta-galactosidase activity in human foreskin fibroblast Hs68 cells. Anal Biochem 325: 337-343.
21. Fieldler F, Hinz H, (1994) No intermediate channelling in stepwise hydrolysis of fluorescein di-beta-D-galactoside by beta-galactosidase. Eur J Biochem 222: 75-81.
22. Whitesides GM, Ostuni E, Takayama S, Jiang XY, Ingber DE, (2001) Soft lithography in biology and biochemistry. Annual Review of Biomedical Engineering 3: 335-373.
23. Weibel DB, Diluzio WR, Whitesides GM, (2007) Microfabrication meets microbiology. Nat Rev Microbiol 5: 209-218.
24. Lenshof A, Laurell T, (2010) Continuous separation of cells and particles in microfluidic systems. Chem Soc Rev 39: 1203-1217.
25. Yoshida K, Nakayama K, Ohtsuka M, Kuru N, Yokomizo Y, et al. (2007) MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate. Bioorg Med Chem 15: 7087-7097.
26. Nishino K, Senda Y, Yamaguchi A, (2008) The AraC-family regulator GadX enhances multidrug resistance in Escherichia coli by activating expression of mdtEF multidrug efflux genes. J Infect Chemother 14: 23-29.
27. Mokhonov VV, Mokhonova EI, Akama H, Nakae T, (2004) Role of the membrane fusion protein in the assembly of resistance-nodulation-cell division multidrug efflux pump in Pseudomonas aeruginosa. Biochem Biophys Res Commun 322: 483-489.
28. Sekiguchi J, Asagi T, Miyoshi-Akiyama T, Fujino T, Kobayashi I, et al. (2005) Multidrug-resistant Pseudomonas aeruginosa strain that caused an outbreak in a neurosurgery ward and its aac(6′)-Iae gene cassette encoding a novel aminoglycoside acetyltransferase. Antimicrob Agents Chemother 49: 3734-3742.
29. Vaara M, (1993) Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria. Antimicrob Agents Chemother 37: 354-356.
30. Vaara M, (1992) Agents that increase the permeability of the outer membrane. Microbiol Rev 56: 395-411.
31. Vaara M, Porro M, (1996) Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric bacteria. Antimicrob Agents Chemother 40: 1801-1805.
32. Vaara M, Siikanen O, Apajalahti J, Fox J, Frimodt-Moller N, et al. (2010) A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob Agents Chemother 54: 3341-3346.
33. Vingsbo Lundberg C, Vaara T, Frimodt-Moller N, Vaara M, (2010) Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice. J Antimicrob Chemother 65: 981-985.
34. Vaara M, Vaara T, (1983) Polycations as outer membrane-disorganizing agents. Antimicrob Agents Chemother 24: 114-122.
35. Vaara M, Vaara T, (1983) Polycations sensitize enteric bacteria to antibiotics. Antimicrob Agents Chemother 24: 107-113.
36. Viljanen P, Vaara M, (1984) Susceptibility of gram-negative bacteria to polymyxin B nonapeptide. Antimicrob Agents Chemother 25: 701-705.
37. Hancock RE, Wong PG, (1984) Compounds which increase the permeability of the Pseudomonas aeruginosa outer membrane. Antimicrob Agents Chemother 26: 48-52.
38. Nagano K, Nikaido H, (2009) Kinetic behavior of the major multidrug efflux pump AcrB of Escherichia coli. Proc Natl Acad Sci U S A 106: 5854-5858.
39. Kaatz GW, Moudgal VV, Seo SM, Kristiansen JE, (2003) Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. Antimicrob Agents Chemother 47: 719-726.
40. Viveiros M, Martins A, Paixao L, Rodrigues L, Martins M, et al. (2008) Demonstration of intrinsic efflux activity of Escherichia coli K-12 AG100 by an automated ethidium bromide method. International Journal of Antimicrobial Agents 31: 458-462.
41. Schumacher A, Steinke P, Bohnert JA, Akova M, Jonas D, et al. (2006) Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other than Escherichia coli. Journal of Antimicrobial Chemotherapy 57: 344-348.
42. Martins A, Spengler G, Rodrigues L, Viveiros M, Ramos J, et al. (2009) pH Modulation of efflux pump activity of multi-drug resistant Escherichia coli: protection during its passage and eventual colonization of the colon. PLoS One 4: e6656.
43. Vidal-Aroca F, Meng A, Minz T, Page MGP, Dreier J, (2009) Use of resazurin to detect mefloquine as an efflux-pump inhibitor in Pseudomonas aeruginosa and Escherichia coli. Journal of Microbiological Methods 79: 232-237.
44. Vaara M, (2009) New approaches in peptide antibiotics. Curr Opin Pharmacol 9: 571-576.
45. Elkins CA, Mullis LB, (2007) Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli. Antimicrobial Agents and Chemotherapy 51: 923-929.